Detalhe da pesquisa
1.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 25(5): 614-625, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38697155
2.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 401(10390): 1773-1785, 2023 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37086745
3.
Analysis of Adverse Events Associated with Trastuzumab Deruxtecan in Patients with Gastric and Breast Cancer: A Retrospective Study.
Biol Pharm Bull
; 47(2): 411-416, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38346748
4.
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 545-550, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38517658
5.
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology.
Int J Clin Oncol
; 29(5): 535-544, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38494578
6.
Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(4): 355-362, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38353907
7.
Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38649648
8.
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 551-558, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38526621
9.
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 559-563, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538963
10.
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology.
Int J Clin Oncol
; 2024 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38578596
11.
Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Int J Clin Oncol
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38696053
12.
Transcriptomic intratumor heterogeneity of breast cancer patient-derived organoids may reflect the unique biological features of the tumor of origin.
Breast Cancer Res
; 25(1): 21, 2023 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36810117
13.
Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study.
Jpn J Clin Oncol
; 53(3): 203-211, 2023 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36484305
14.
Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.
Int J Clin Oncol
; 28(12): 1585-1596, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37787866
15.
[Challenges to International Collaborative Clinical Research and Approval Disparities].
Gan To Kagaku Ryoho
; 50(1): 30-34, 2023 Jan.
Artigo
em Japonês
| MEDLINE | ID: mdl-36759982
16.
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 23(5): 636-649, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35405087
17.
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Cancer Sci
; 113(9): 3169-3179, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35754298
18.
Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.
BMC Cancer
; 22(1): 36, 2022 Jan 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34983437
19.
Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.
Jpn J Clin Oncol
; 52(6): 545-553, 2022 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35296894
20.
Effectiveness of self-help workbook intervention on quality of life in cancer patients receiving chemotherapy: results of a randomized controlled trial.
BMC Cancer
; 21(1): 588, 2021 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34022838